Anabolic and antiresorptive actions of locally delivered bisphosphonates for bone repair
(2018) In Bone and Joint Research 7(10). p.548-560- Abstract
During the last decades, several research groups have used bisphosphonates for local application to counteract secondary bone resorption after bone grafting, to improve implant fixation or to control bone resorption caused by bone morphogenetic proteins (BMps). We focused on zoledronate (a bisphosphonate) due to its greater antiresorptive potential over other bisphosphonates. Recently, it has become obvious that the carrier is of importance to modulate the concentration and elution profile of the zoledronic acid locally. Incorporating one fifth of the recommended systemic dose of zoledronate with different apatite matrices and types of bone defects has been shown to enhance bone regeneration significantly in vivo. We expect the local... (More)
During the last decades, several research groups have used bisphosphonates for local application to counteract secondary bone resorption after bone grafting, to improve implant fixation or to control bone resorption caused by bone morphogenetic proteins (BMps). We focused on zoledronate (a bisphosphonate) due to its greater antiresorptive potential over other bisphosphonates. Recently, it has become obvious that the carrier is of importance to modulate the concentration and elution profile of the zoledronic acid locally. Incorporating one fifth of the recommended systemic dose of zoledronate with different apatite matrices and types of bone defects has been shown to enhance bone regeneration significantly in vivo. We expect the local delivery of zoledronate to overcome the limitations and side effects associated with systemic usage; however, we need to know more about the bioavailability and the biological effects. The local use of BMp-2 and zoledronate as a combination has a proven additional effect on bone regeneration. This review focuses primarily on the local use of zoledronate alone, or in combination with bone anabolic factors, in various preclinical models mimicking different orthopaedic conditions.
(Less)
- author
- Qayoom, I. ; Raina, D. B. LU ; Širka, A. ; Tarasevičius LU ; Tägil, M. LU ; Kumar, A. LU and Lidgren, L. LU
- organization
- publishing date
- 2018-10-03
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Bisphosphonates, Bone repair, Carrier, Ceramic, Local delivery, Zoledronic acid
- in
- Bone and Joint Research
- volume
- 7
- issue
- 10
- pages
- 13 pages
- publisher
- British Editorial Society of Bone & Joint Surgery
- external identifiers
-
- scopus:85056103399
- ISSN
- 2046-3758
- DOI
- 10.1302/2046-3758.710.BJR-2018-0015.R2
- language
- English
- LU publication?
- yes
- id
- 7451a83c-f967-4e79-9ce7-6a248ef3b657
- date added to LUP
- 2018-11-22 14:05:40
- date last changed
- 2022-03-25 05:58:57
@article{7451a83c-f967-4e79-9ce7-6a248ef3b657,
abstract = {{<p>During the last decades, several research groups have used bisphosphonates for local application to counteract secondary bone resorption after bone grafting, to improve implant fixation or to control bone resorption caused by bone morphogenetic proteins (BMps). We focused on zoledronate (a bisphosphonate) due to its greater antiresorptive potential over other bisphosphonates. Recently, it has become obvious that the carrier is of importance to modulate the concentration and elution profile of the zoledronic acid locally. Incorporating one fifth of the recommended systemic dose of zoledronate with different apatite matrices and types of bone defects has been shown to enhance bone regeneration significantly in vivo. We expect the local delivery of zoledronate to overcome the limitations and side effects associated with systemic usage; however, we need to know more about the bioavailability and the biological effects. The local use of BMp-2 and zoledronate as a combination has a proven additional effect on bone regeneration. This review focuses primarily on the local use of zoledronate alone, or in combination with bone anabolic factors, in various preclinical models mimicking different orthopaedic conditions.</p>}},
author = {{Qayoom, I. and Raina, D. B. and Širka, A. and Tarasevičius and Tägil, M. and Kumar, A. and Lidgren, L.}},
issn = {{2046-3758}},
keywords = {{Bisphosphonates; Bone repair; Carrier; Ceramic; Local delivery; Zoledronic acid}},
language = {{eng}},
month = {{10}},
number = {{10}},
pages = {{548--560}},
publisher = {{British Editorial Society of Bone & Joint Surgery}},
series = {{Bone and Joint Research}},
title = {{Anabolic and antiresorptive actions of locally delivered bisphosphonates for bone repair}},
url = {{http://dx.doi.org/10.1302/2046-3758.710.BJR-2018-0015.R2}},
doi = {{10.1302/2046-3758.710.BJR-2018-0015.R2}},
volume = {{7}},
year = {{2018}},
}